Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractionated SRS and Bevacizumab for Brain Metastases
NCT02672995Phase 1Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab in brain metastasis (BM), sponsored by National Taiwan University Hospital. Primary endpoint: Maximum tolerated dose at 4 months. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
brain metastasis (BM)
Beyond the preview
Go deeper on NCT02672995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672995.